ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1268

Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?

Hakan Emmungil1, Ufuk İlgen 1, Sezin Turan 1, Samet Yaman 2 and Orhan Küçükşahin 3, 1Trakya University, Edirne, Turkey, 2Yıldırım Beyazıt University, Ankara, Turkey, 3Liv Hospital, Ankara, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Colchicine, Familial Mediterranean fever, pharmacokinetics and drug resistance

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Colchicine is the mainstay of treatment for prevention of attacks and associated amyloidosis in Familial Mediterranean Fever (FMF). Two approved colchicine preparations are currently available in Turkish market. In case of resistance or adverse effects, it is a common practice for Turkish rheumatologists to change the colchicine preparation with an imported one. The aim of this study was to assess the benefit of the imported colchicine in Turkish adult patients with FMF resistant or intolerant to domestic colchicine preparations.

Methods: Adult patients followed up with a clinical diagnosis of FMF, meeting Tel Hashomer criteria, resistant or intolerant to domestic colchicine preparations, and under treatment with a particular brand of imported colchicine were identified retrospectively and included in the study. Patients using anti-interleukin-1 or other biological agents were excluded. Disease characterisitcs, MEditerranean FeVer gene (MEFV) mutations, attack frequencies before and after the imported colchicine were specified for each patient from their medical records. Resistance to colchicine was defined as suggested by the EULAR. Frequency of attacks and colchicine doses before and after the imported colchicine were compared. Mann-Whitney U or Kruskal-Wallis tests were used for comparison of distributions of unrelated samples and Wilcoxon signed rank test for repeated measurements. p< 0.05 was considered statistically significant.

Results: A total of 59 patients were included in the study. Thirty-six (61%) patients were female and median age was 29 (interquartile range: 22-38) years. Median duration of disease was 6 (interquartile range: 2-14) years. There were 46 (78%) patients carrying exon 10 mutations in homozygous or compound heterozygous forms. Eight (14%) patients had isolated exon 10 mutations in heterozygous form and three (5.1%) had an exon 10 and the E148Q mutations together. No patient had isolated E148Q mutation in homo- or heterozygous forms. Mutant allele frequencies and characteristics of the attacks were given in Figure 1.

Fifty (84.8%) and 9 (15.2%) patients had resistance and intolerance to domestic colchicine preparations, respectively. Median number of attacks in the last three months before the imported colchicine was three (range 0-6). Although daily colchicine doses did not differ before and after the imported colchicine, number of attacks per year significantly reduced both in resistant and intolerant cases (Figure 2) after a median follow up of 19 (range 8-60) months under the imported colchicine. The decrease in number of attacks were more prominent in resistant cases (Figure 2).

Pharmacokinetic studies performed with different brands of colchicine after single oral doses in healthy subjects or FMF patients with normal renal and hepatic functions were summarized in Table 1.

Conclusion: Turkish FMF patients with ongoing attacks under domestic colchicine preparations may benefit from imported colchicine. This seems to be explainable by difference in pharmacokinetic properties of different colchicine preparations.

Figure 1. a. Allelic frequencies of the MEFV gene mutations. b. Characteristics of the attacks.

Figure 2. Distributions of attacks and daily colchicine doses before and after the imported colchicine.

Table 1. Pharmacokinetic properties of different colchicine preparations after single oral doses in subjects with normal renal and hepatic functions.


Disclosure: H. Emmungil, None; U. İlgen, None; S. Turan, None; S. Yaman, None; O. Küçükşahin, None.

To cite this abstract in AMA style:

Emmungil H, İlgen U, Turan S, Yaman S, Küçükşahin O. Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/different-colchicine-preparations-for-familial-mediterranean-fever-are-they-the-same/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-colchicine-preparations-for-familial-mediterranean-fever-are-they-the-same/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology